Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:BLRX NASDAQ:EVAX NASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.56+2.9%$2.91$2.00▼$5.00$16.58M2.27.17 million shs74,049 shsBLRXBioLineRx$3.74+4.2%$4.24$2.30▼$30.34$15.94M1.1538,228 shs51,310 shsEVAXEvaxion A/S$3.25+4.8%$2.65$1.20▼$17.75$4.56M0.13126,617 shs74,198 shsLEXXLexaria Bioscience$0.79+0.9%$0.89$0.77▼$4.38$15.51M0.79188,490 shs151,535 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%+2.89%+36.92%+47.11%+12.96%BLRXBioLineRx0.00%+0.81%-17.07%+2.19%-87.36%EVAXEvaxion A/S0.00%+12.85%+19.93%+72.87%-79.69%LEXXLexaria Bioscience0.00%-3.26%-21.50%-27.93%-75.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.4226 of 5 stars0.03.00.00.01.51.70.0BLRXBioLineRx3.411 of 5 stars3.85.00.00.02.60.01.3EVAXEvaxion A/S2.4974 of 5 stars3.52.00.00.02.51.70.6LEXXLexaria Bioscience3.3777 of 5 stars3.55.00.00.01.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ABLRXBioLineRx 3.50Strong Buy$26.00595.19% UpsideEVAXEvaxion A/S 3.00Buy$10.00207.69% UpsideLEXXLexaria Bioscience 3.00Buy$4.00404.54% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, AIMD, LEXX, and BLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.006/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K829.48N/AN/A$2.46 per share1.45BLRXBioLineRx$28.94M0.55N/AN/A$4.71 per share0.79EVAXEvaxion A/S$3.34M1.36N/AN/A$4.44 per share0.73LEXXLexaria Bioscience$460K33.71N/AN/A$0.48 per share1.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/4/2025 (Estimated)BLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-45.34%-49.74%-17.54%N/AEVAXEvaxion A/S-$10.57M-$1.32N/AN/AN/A-316.03%-319.52%-63.56%10/30/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/ALatest EVAX, AIMD, LEXX, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BLRXBioLineRx-$0.35-$1.00-$0.65-$1.00$0.66 million$0.30 million8/14/2025Q2 2025EVAXEvaxion A/S-$0.50-$0.76-$0.26-$0.76N/A$0.04 million8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/A7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/27/2025Q1 2025EVAXEvaxion A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.962.882.61BLRXBioLineRx0.332.062.04EVAXEvaxion A/S1.733.422.01LEXXLexaria BioscienceN/A3.903.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABLRXBioLineRx1.56%EVAXEvaxion A/S11.04%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%BLRXBioLineRx1.10%EVAXEvaxion A/S41.64%LEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.66 million4.17 millionNot OptionableBLRXBioLineRx404.26 million4.22 millionOptionableEVAXEvaxion A/S601.40 million819,000No DataLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableEVAX, AIMD, LEXX, and BLRX HeadlinesRecent News About These CompaniesLexaria Bioscience stock rises after completion of GLP-1 study milestoneAugust 14, 2025 | investing.comLexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 studyAugust 14, 2025 | msn.comLexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" MilestoneAugust 14, 2025 | thenewswire.comTLexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" MilestoneAugust 14, 2025 | accessnewswire.comAGLP-1 "Arms Race" Broadens to Include Dozens of CompaniesAugust 6, 2025 | accessnewswire.comALEXX: Third Quarter ResultsJuly 31, 2025 | finance.yahoo.comInsider Buying: Lexaria Bioscience Corp. (NASDAQ:LEXX) Director Buys 11,900 Shares of StockJuly 31, 2025 | insidertrades.comLexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 StudyJuly 28, 2025 | thenewswire.comTLexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 StudyJuly 28, 2025 | accessnewswire.comALexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-IndustryJuly 23, 2025 | thenewswire.comTLexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-IndustryJuly 23, 2025 | accessnewswire.comALEXX - Lexaria Bioscience Corp Dividends - MorningstarJuly 12, 2025 | morningstar.comMLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | accessnewswire.comALexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | thenewswire.comTLexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | accessnewswire.comALexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | thenewswire.comTLexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deLexaria Attending BIO International ConventionJune 5, 2025 | accessnewswire.comALexaria Attending BIO International ConventionJune 5, 2025 | thenewswire.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, AIMD, LEXX, and BLRX Company DescriptionsAinos NASDAQ:AIMD$3.56 +0.10 (+2.89%) As of 08/22/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioLineRx NASDAQ:BLRX$3.74 +0.15 (+4.18%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.75 +0.01 (+0.29%) As of 08/22/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Evaxion A/S NASDAQ:EVAX$3.25 +0.15 (+4.84%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.24 0.00 (-0.15%) As of 08/22/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Lexaria Bioscience NASDAQ:LEXX$0.79 +0.01 (+0.88%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.81 +0.02 (+2.30%) As of 08/22/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access